Alligator Bioscience AB (OSTO:ATORX) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ATORX Alligator Bioscience AB OSTO:ATORX
39 GF Score
Price kr0.17
GF Value kr0.01
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Alligator Bioscience AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

OSTO:ATORX vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alligator Bioscience AB Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Margin of Safety % (DCF Dividends Based) falls into.


OSTO:ATORX
39GF Score
Alligator Bioscience AB OSTO:ATORX
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alligator Bioscience AB (OSTO:ATORX) Overvalued in 2026?

Based on GuruFocus' analysis, Alligator Bioscience AB stock appears to be overvalued. The current stock price of kr0.17 is trading 1612% above its estimated GF Value™ of kr0.01. GuruFocus considers Alligator Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:ATORX:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: kr0.01 vs. price of kr0.17 (1612% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the OSTO:ATORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alligator Bioscience AB Business Description

Other Exchanges 0RK9:UK7AL0:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score

Get the complete analysis for OSTO:ATORX

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.17
Price
kr0.01
GF Value